Qubigen

Daily food choices can be so unhealthy. Further evidence that diet has a huge impact on our gut health

🚨 ‼️ Reminder! We could see a massive shift in AI. GROK 4 can do great as a reasoning engine, and on generic, public data sources. But that simply won’t work for designing new medicines - as the relevant data is behind institutional firewalls that only Qubigen could access…

Qubigen's federated learning enables collaborative AI training on decentralized, private datasets without data sharing, preserving IP and privacy. This gives it an edge in drug design by accessing exclusive pharma data for more accurate, novel molecule generation—unlike…

At Qubigen, our latest pilot study showed that ‘dark’ reactions, real-world failed chemical synthesis reactions, may be one of the most underutilized assets in medicinal chemistry and drug development. qubigen.com/post/unlocking…

Qubigen Advances in the TBXT Challenge with Promising Early Compounds and Second-Round AI Optimization Underway qubigen.com/post/qubigen-a…

Qubigen is pleased to announce the signing of a Master Data Access Agreement with the University of Adelaide, formalizing a cooperative relationship to explore AI driven approaches to drug design using proprietary scientific data. qubigen.com/post/qubigen-a…

Qubigen Wraps Up BIO 2025 with Over 45 Strategic Meetings and High-Impact Engagements, highlighted by CEO Jonathan Hall’s presentation at the BIO International Convention 2025. qubigen.com/post/qubigen-w…

Qubigen is thrilled to announce that our CEO, Dr. Jonathan M. M. Hall, will be presenting at the 2025 BIO International Convention in Boston. Date: June 18, 2025 Time: 1:45 PM – 2:00 PM linkedin.com/posts/qubigen_…

Qubigen and the University of Melbourne Sign Memorandum of Understanding to Explore Drug Development Collaboration. linkedin.com/posts/qubigen_…

Qubigen Joins the TBXT Challenge to Accelerate Discovery of Lead Candidates for Chordoma. linkedin.com/posts/qubigen_…

Following two recent milestones, Qubigen is actively seeking collaborators, clients, and Data Access Partners from academic institutes and from industry. Find out more: linkedin.com/posts/qubigen_…

Qubigen is revolutionizing drug design with Federated AI! We’re seeking a visionary lead investor to join us. Our biotech platform, backed by SYNthesis BioVentures’ pre-seed funding, is delivering breakthroughs—unlocking our second tranche early.

🚀𝙌𝙪𝙗𝙞𝙜𝙚𝙣 𝙞𝙨 𝙖𝙘𝙘𝙚𝙡𝙚𝙧𝙖𝙩𝙞𝙣𝙜 𝙩𝙝𝙚 𝙛𝙪𝙩𝙪𝙧𝙚 𝙤𝙛 𝙁𝙚𝙙𝙚𝙧𝙖𝙩𝙚𝙙 𝘼𝙄 for drug design, and we’re on the hunt for a visionary lead investor to join our journey! Our innovative platform is transforming biotech 🧫, and we’ve already secured strategic…

Congratulations Dr Ziad!

ᴄᴏʟʟᴀʙᴏʀᴀᴛɪᴏɴ - ᴡɪᴛʜᴏᴜᴛ ᴇxᴘᴏꜱɪɴɢ ꜱᴇᴄʀᴇᴛꜱ. Qubigen leverages robust network connectivity to excel in AI-driven drug design. Our global federated AI system enables cross-border collaboration through GigCity and SABRENet shorturl.at/j7PhJ

Qubigen • Intelligent Drug Design

Researchers from the Parkinson’s Disease Research Centre at WEHI & the National Drug Discovery Centre have discovered a molecule that blocks cell death, a finding that could lead to next-generation drugs for neurogenerative condition. wehi.edu.au/news/cell-deat…

A perfect reason for AI to inherit even more exciting capital activity in the market - as people strive for cheaper, faster and more effective drug development methods

🎙️Dr Shehara Mendis from the @gibbs_lab spoke with @3RRRFM about the FORECAST-2 study, which has the potential to revolutionise the way people with #BowelCancer are treated. 🎧Listen from the 45:58 mark to hear more rrr.org.au/explore/progra…

Decentralised AI is coming - it is upon us